Transition from secukinumab to adalimumab in COVID-19-induced psoriasis flare-up treatment: A case report

Yuting Chen; Yangyang Qiu; Meiqing Chen; Ling Huang; Xinyu Lin; Xiaoyan Qiu; Yi Wei; Lujuan Gao

doi:10.1002/ccr3.8047

Transition from secukinumab to adalimumab in COVID-19-induced psoriasis flare-up treatment: A case report

Clin Case Rep. 2023 Oct 11;11(10):e8047. doi: 10.1002/ccr3.8047. eCollection 2023 Oct.

Authors

Yuting Chen¹, Yangyang Qiu¹, Meiqing Chen¹, Ling Huang¹, Xinyu Lin¹, Xiaoyan Qiu¹, Yi Wei^{1

2}, Lujuan Gao^{1

2}

Affiliations

¹ Department of Dermatology, Zhongshan Hospital (Xiamen) Fudan University Xiamen China.
² Department of Dermatology, Zhongshan Hospital Fudan University Shanghai China.

Abstract

Coronavirus disease 2019 (COVID-19) is known to trigger systemic inflammation and elicit immune responses, which may disrupt the delicate balance of cytokines involved in psoriatic regulation. Compared to other therapies in dermatology, biologics used for immune-mediated dermatological diseases have been more extensively studied during the COVID-19 pandemic. Herein, we report a case of flare-up of previously well-controlled psoriasis shortly after infection with COVID-19, with treatment transition from secukinumab to adalimumab.

Keywords: COVID‐19; adalimumab; psoriasis; secukinumab.

Publication types

Case Reports